Jonathan Young - 12 Aug 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
12 Aug 2025
Net transactions value
-$333,576
Form type
4
Filing time
13 Aug 2025, 18:37:42 UTC
Previous filing
02 Jul 2025
Next filing
04 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Young Jonathan Chief Operating Officer C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO /s/ Jonathan Young 13 Aug 2025 0001779805

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $263,750 +12,500 +6.3% $21.10 209,984 12 Aug 2025 Direct F1
transaction AKRO Common Stock Sale $532,137 -11,151 -5.3% $47.72 198,833 12 Aug 2025 Direct F1, F3
transaction AKRO Common Stock Sale $65,189 -1,349 -0.68% $48.32 197,484 12 Aug 2025 Direct F1, F4
holding AKRO Common Stock 20,000 12 Aug 2025 By EA Irrevocable Trust F2
holding AKRO Common Stock 20,000 12 Aug 2025 By CM Irrevocable Trust F2
holding AKRO Common Stock 20,000 12 Aug 2025 By JL Irrevocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -12,500 -15% $0.000000 69,982 12 Aug 2025 Common Stock 82,482 $21.10 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, previously adopted by the Reporting Person.
F2 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.21 to $48.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.22 to $48.61, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
F5 This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2021